Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ADH-503 (GB1275) 是一种可口服的变构CD11b 激动剂,可以导致与肿瘤相关的巨噬细胞重新极化,可减轻骨髓细胞的免疫抑制,并增强树突状细胞的反应。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 196 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,280 | 现货 | ||
50 mg | ¥ 1,930 | 现货 | ||
100 mg | ¥ 2,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 522 | 现货 |
产品描述 | ADH-503 (GB1275) is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression. |
体外活性 | The partial activation of CD11b by a small-molecule agonist (ADH-503) leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhanced dendritic cell responses.?These actions, in turn, improve antitumor T cell immunity and render checkpoint inhibitors effective in previously unresponsive PDAC models.?These data demonstrate that molecular agonism of CD11b reprograms immunosuppressive myeloid cell responses and potentially bypasses the limitations of current clinical strategies to overcome resistance to immunotherapy. |
体内活性 | ADH-503 had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively. |
动物实验 | Animal Model:Male rats.Dosage:30,100 mg/kg (Pharmacokinetic Analysis). Administration:Oral gavage twice a day; on days 1 and 5 |
别名 | GB1275 |
分子量 | 524.7 |
分子式 | C27H28N2O5S2 |
CAS No. | 2055362-74-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.25 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9059 mL | 9.5293 mL | 19.0585 mL | 47.6463 mL |
5 mM | 0.3812 mL | 1.9059 mL | 3.8117 mL | 9.5293 mL | |
10 mM | 0.1906 mL | 0.9529 mL | 1.9059 mL | 4.7646 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ADH-503 2055362-74-6 Immunology/Inflammation Complement System GB1275 tumor-infiltrating ADH 503 CD11b GB 1275 Inhibitor tumorassociated dendritic immunosuppressive ADH503 macrophages repolarization allosteric inhibit orally GB-1275 inhibitor